Mineralys Therapeutics Inc. (MLYS) continues to advance its aldosterone synthase inhibitor program with pivotal trial recognition, strengthened financials, and upcoming data readouts that place the company on the radar for investors tracking developments in hypertension and cardiorenal therapies.
Company Overview
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com